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Abstract:
Mobilized peripheral blood is the most common graft source for allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning. In assessing the effect of donor cell dose and graft composition on major transplant outcomes in the reduced-intensity setting, prior studies have focused primarily on CD34+ cell dose and report conflicting results, especially in relation to survival endpoints. While the impact of total nucleated cell dose has been less frequently evaluated, available studies suggest higher total nucleated cell dose is associated with improved survival outcomes in the reduced-intensity setting. In order to further explore the relationship between CD34+ cell dose and total nucleated cell dose on reduced-intensity transplant outcomes, we analyzed the effect of donor graft dose and composition on outcomes of 705 patients with hematological malignancies who underwent reduced-intensity peripheral blood stem cell transplantation at the Dana Farber Cancer Institute from [2000] [2001] [2002] [2003] [2004] [2005] [2006] [2007] [2008] [2009] [2010] . By multivariable analysis, we found higher total nucleated cell dose (top quartile; 10^6/kg) had no significant effect on graft-versus-host disease or survival outcomes. These data suggest total nucleated cell dose is a more relevant prognostic variable for reduced-intensity transplant outcomes than the more commonly studied CD34+ cell dose.
Introduction:
The impact of graft composition and donor cell dose on allogeneic hematopoietic stem cell transplantation (HCT) outcomes has been extensively studied in myeloablative conditioning (MAC) transplantation, and CD34+ cell dose is often utilized as the product-related variable of choice for outcomes analysis. Given that cell-based graft vs. tumor effect is the central therapeutic mechanism in reduced-intensity conditioning (RIC) transplantation, product-related variables may have an even more significant impact on transplant outcomes in the RIC setting. However, relatively few studies have reported on product-related outcomes data in RIC transplants. These studies have primarily focused on CD34+ cell dose, most
reporting that higher CD34+ cell doses are associated with more rapid engraftment with variable effect on GVHD incidence and survival outcomes. 1-5 Gomez-Almaguer and colleagues reported on 138 recipients of RIC HCT, showing that higher CD34+ doses correlated with improved overall survival. 6 A CIBMTR registry analysis of 1054 RIC HCT recipients found that lower CD34+ doses correlated with increased transplant related mortality and decreased overall survival. 7 In contrast, Remberger and colleagues reported that higher CD34+ doses were actually associated with higher relapse rates and lower overall survival.
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Relative to CD34+ cell dose, TNC dose has been less frequently studied.
However, in the limited number of studies that have examined TNC, a trend toward improved survival outcomes with higher TNC dose, independent of CD34+ dose, has been reported. 9-10 The current study examines the impact of both TNC and CD34+ cell dose on major transplant outcomes in a cohort of 705 consecutive RIC allogeneic peripheral blood HCT patients.
Methods:
We analyzed data from 705 consecutive patients with hematologic malignancy undergoing reduced-intensity conditioning utilizing granulocyte-colony-stimulating factor mobilized peripheral blood mononuclear cells as a donor source. Patients who underwent either in vivo T-cell depletion (TCD) with antithymocyte globulin or ex-vivo TCD were excluded from the study. All patients had at least 3 years of follow-up after transplant. All patients provided consent for the use of protected health data for research as approved by a common institutional review board of the Dana-Farber/Harvard Cancer Center.
Definitions/ End points
Neutrophil engraftment was defined as the first day of an absolute neutrophil count >500/μL on 3 consecutive measurements. Platelet recovery was defined as the first day of 2 consecutive measurements of >20,000/ μ L (unsupported). Acute and chronic GVHD was graded by consensus grading criteria and cumulative incidence was calculated through day +200 after HSCT. Chronic GVHD was defined clinically by treating physicians utilizing standard criteria ultimately supplanted by NIH Consensus Conference recommendations.
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Relapse was defined as disease recurrence documented by morphologic, histologic or radiographic means. Treatment related mortality was defined as death while in continuous remission. Progression free survival (PFS) was defined as the time from transplantation to relapse or death from any cause, and overall survival (OS) was defined as the time from transplantation to death from any cause.
Statistical methods:
For each cell type of interest, cell dose level is classified into groups using quartile cutoffs ( 
Results:
Patients Patient characteristics are listed in Table 2 . The vast majority of patients (99%) received reduced-intensity conditioning with busulfan and fludarabine (IV busulfan total dose of 3.2 or 6.4 mg/kg; IV fludarabine total dose of 120mg/m 2 ). GVHD prophylaxis was mostly tacrolimus based, with or without sirolimus (74% vs. 24%, respectively). The median age was 57 years with a range from 18-74 years. Sixty-two percent of patients were male. AML was the most common diagnosis (29% During the first year, all patients received acyclovir as herpes simplex virus/varicella zoster virus (HSV/VZV) prophylaxis, and sulfamethoxazole/trimethoprim or atovaquone as prophylaxis against Pneumocystis jirovecii. Patients were monitored for cytomegalovirus (CMV) reactivation during the first 100 days after transplantation, and pre-emptive therapy with valganciclovir was given if CMV reactivation occurred. Routine use of G-CSF to accelerate engraftment was utilized in most patients.
Engraftment:
TNC dose did not influence the onset or durability of engraftment. In contrast, as expected, time to ANC engraftment was significantly shorter for the highest quartile of CD34+ cells infused/kg compared with the lower three quartiles combined in a competing risk regression (p=0.0004). This analysis censored subjects who did not nadir below an absolute neutrophil count of 500/ μ L.
GVHD:
Neither TNC nor CD34+ cell dose affected grades II-IV acute GVHD. However, there was a significant association between TNC dose and the development of chronic GVHD. The 1-yr cumulative incidence of cGVHD across the four TNC dose quartiles (Q1-Q4) were 37%, 44%, 47%, 52%, respectively (p=0.017). In a regression model evaluating the quartiles, Q1 was associated with decreased risk (HR=0.80, p=0.0004) vs. Q4. Dichotomized regression analysis was performed by collapsing the top three quartiles and comparing to Q1. In this dichotomized analysis, Q1 was associated with decreased risk of cGVHD vs. Q2+Q3+Q4 (HR=0.71, p=0.0063, Figure 2 ). There was no association between CD34+ cell dose and cGVHD.
Relapse:
The 3-yr cumulative incidence of relapse across the four TNC dose groups (Q1-Q4) was 54%, 60%, 54%, 42%, respectively (p=0.017). In a regression model evaluating the quartiles, each of the first three quartiles was associated with increased risk of relapse compared to Q4 (HR=1.41, 1.63, 1.53; p=0.029, 0.0013, 0.0068, respectively). In a dichotomized regression analysis performed by collapsing Q1, Q2 and Q3, Q4 was associated with decreased risk of relapse when compared with Q1+Q2+Q3 (HR=0.66, p=0.0012, Figure 3A ). After adjusting for chronic GVHD as a time-dependent covariate in a Cox model, high TNC (Q4 vs. Q1+Q2+Q3) was still significantly associated with better PFS (p<0.0001) and lower relapse rate (p <0.0001).
CD34+ cell dose did not impact relapse rates. The 3-yr cumulative incidence of relapse across the four CD34+/kg dose groups (Q1-Q4) was 48%, 51%, 51%, 59%, respectively (p=0.20). In dichotomized regression analysis of CD34+ cell dose, no significant effect was found by collapsing Q1, Q2 and Q3 vs. Q4 (p=0.15), or by collapsing Q2+Q3+Q4 vs. Q1 (p=0.13).
Non-Relapse Mortality (NRM):
There was no association between TNC ( Figure 3B ) or CD34+ cell infusion numbers and the 3-yr cumulative incidence of NRM.
Progression Free (PFS) and Overall Survival (OS):
The 3-yr PFS across the four TNC dose groups (Q1-Q4) was 37%, 32%, 32%, 46%, respectively (p=0.029), and 3-yr OS In an effort to elucidate which components of the graft could account for the significant impact of TNC on cGVHD, relapse, PFS, and OS, we performed an exploratory analysis on a subset of patients in which the CD3+ (n=445), CD4+ (n=443) and CD8+ (n=444) fraction of the graft was reliably enumerated. No association between CD3+, CD4+ or CD8+ cell count and these outcomes was identified; either because the analysis was underpowered to demonstrate a significant difference or because other specific cellular components rather than total CD3+, CD4+ or CD8+ cell count impacted these outcomes.
Total CD34+ cell dose and TNC/kg
Exploratory analysis was performed for total CD34+ dose as well as TNC/kg, demonstrating no significant association between either total CD34+ dose or TNC/kg and the aforementioned transplant outcomes.
Discussion:
The majority of studies analyzing the impact of graft composition on major transplant outcomes in RIC HSCT have focused on the influence of CD34+ cell dose, reporting mixed results with regard to survival outcomes, engraftment and incidence of GVHD. In their study of 86 patients who underwent RIC allogeneic HSCT, Perez-Simon and colleagues reported an increased incidence of chronic GVHD and decreased relapse rates with increased CD34+/kg (depending on disease state at transplant), but no significant effect on overall survival or event free survival. 1 Pulsipher and colleagues reported on 160 patients undergoing RIC allogeneic HSCT and showed more rapid engraftment, reduced TRM and better 3-year OS in the high CD34+ cell-dose (>4.5 x 10 6 cells/kg) cohort without demonstrating any associated increase in the incidence of acute or chronic GVHD. 4 In an analysis of 1054 reduced-intensity transplant recipients reported to the CIBMTR from 2002 to 2011, Torlen and colleagues determined that low CD34+ cell dose (< 4 x 10 6 CD34+ cells/kg) was associated with increased non-relapse mortality and inferior overall survival.
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In a recent analysis, Remberger and colleagues reported inferior outcomes for patients receiving less than 2.5 x 10 6 CD34+ cells/kg, but also poorer survival due to increased relapse rates in patients receiving over 11 x 10 6 CD34+ cells/kg, albeit in pooled analyses of both MAC and RIC transplant patients. 8 These examples typify the myriad published analyses that have, thus far, failed to demonstrate reproducible, consensus data regarding the effect of CD34+ cell dose on common RIC transplant outcomes.
1-5, [13] [14] [15] [16] [17] [18] In contrast to CD34+ cell dose, there have been only a limited number of studies that report on the effect of TNC dose on RIC transplant outcomes. Baron and colleagues analyzed graft composition data from 125 RIC patients, showing a nonsignificant, but appreciable trend (HR 0.08, p=0.06), toward improved OS as well as PFS with higher TNC dose. 9 In their study of 253 AML patients undergoing RIC transplant, Gorin and colleagues reported CD34+/kg cell dose to have no effect on either GVHD or OS, but that increased TNC dose was independently associated with more chronic GVHD as well as improved overall survival.
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In the aforementioned study by Remberger and colleagues, TNC dose showed no correlation with survival outcomes, relapse rates, engraftment or GVHD. Similar to CD34+ cell dose discussed above, albeit with the caveat of far less published data, the impact of TNC dose on RIC transplant outcomes remains undefined.
To our knowledge, our current single institution study of 705 RIC patients is the largest to date analyzing product-related variables on transplant outcomes in the reduced-intensity setting. We report improved survival data (OS/PFS) with higher TNC dose, whereas CD34+ cell dose (total and per kg) was found to have no significant effect on these critical outcomes.
Based on recent studies demonstrating an association between RIC transplant survival outcomes and absolute lymphocyte count recovery 19 as well as donor chimerism, 20 we analyzed the effect of TNC dose on these additional prognostic indicators, but failed to demonstrate any significant association. Nevertheless, our findings support prior reports 9-10 indicating that TNC dose is potentially a more relevant product-related variable than CD34+ cell dose with regard to RIC transplant outcomes. It is unlikely that the top quartile of total nucleated cells enumerated in our cohort (>10.9 x 10 10 cells) represents the ideal cell target across transplant center collection facilities despite its association with lower relapses rates and improved survival. Rather, our experience may suggest that "more is better" when it comes to
TNC. An improved survival benefit with higher TNC doses should influence those current RIC transplant protocols that cap the TNC infusion dose. Importantly, our analysis showed no significant association between TNC and CD34+ cell and reduced relapse rates with increased CD8+ cells, with no significant effect of CD3+, CD4+ or CD34+ subsets on these outcomes (of note, TNC dose was not reported in this study). 24 While our subset analysis of CD3+, CD4+ and CD8+ cell dose in approximately 445 RIC transplant patients failed to demonstrate any significant association between these T-lymphocyte subsets and our observed transplant outcomes, these studies both suggest that the CD34 negative fraction of the graft is most critical to transplant outcome after reduced-intensity conditioning. These findings support more comprehensive analysis of graft subset populations as a compelling direction for future research. Such analysis could potentially elucidate a cell subset (or synergistic groups of cell subsets) within the TNC population that most directly confers a survival benefit, allowing for the future possibility of improving RIC transplant outcomes with directed graft manipulation. 
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